Case Report
IntroductIon
New oral anticoagulants (NOACs) have been approved for the prophylaxis and treatment of arterial and venous thromboembolism. Although they showed to have similar or superior safety compared with Vitamin K antagonists (VKAs), bleedings are not uncommon in patients treated by NOACs and life-threatening events have been reported. The most common sites of bleeding include gastrointestinal, genitourinary, and intracranial ones. Hemopericardium is a rare eventuality in patients treated with NOACs. Herein, we describe the first case report, to our knowledge, of a slowly accumulating spontaneous hemopericardium in a patient treated with rivaroxaban who did not take any other herbal products or drugs that may increase rivaroxaban blood levels.
caSe report
A 88-year-old Caucasian woman was admitted to the emergency room complaining of orthopnea and weakness with gradual onset. Her medical history included dyslipidemia, obesity, and permanent pacemaker implantation for sick sinus syndrome in 2003. Her routine drug therapy consisted of esomeprazole and rosuvastatin. Six months before the onset of the symptoms, full dosage rivaroxaban (20 mg once daily) was prescribed for permanent atrial fibrillation, according to her estimated glomerular filtration rate (63 ml/min). The patient denied fever, weight loss, and any history of trauma in the previous weeks. The heart rate was 70 beats/min, blood pressure was 130/70 mmHg, and oxygen saturation on room air was 98%. The physical examination revealed jugular vein congestion, faint heart sound, no murmurs, and leg swelling. Electrocardiogram showed atrial fibrillation with ventricular pacing. The laboratory tests did not reveal significant alterations, including leukocytosis or anemia or hypothyroidism. A chest radiograph showed a significant cardiomegaly without pleural effusion and a transthoracic echocardiogram (TTE) found a 36-mm circumferential pericardial effusion without the signs of tamponade [ Figures 1 and 2 and Video 1]. The patient was transferred to
We describe a case of an 88-year-old woman with a severe bluntly ematic pericardial effusion. Radiological and laboratory examinations excluded all the most common causes of hemopericardium, and the diagnosis of spontaneous hemopericardium associated with the treatment with rivaroxaban was made. This is the first case report describing a hemopericardium in a patient treated with rivaroxaban who did not take other herbal products or drugs that may significantly increase rivaroxaban blood levels. This report emphasizes the need for the careful use of new oral anticoagulants, and the importance of taking in mind uncommon side effects. Spontaneous hemopericardium should be considered in these patients.
the intensive care unit and he underwent pericardiocentesis to provide a relief of symptoms. Rivaroxaban was discontinued before the drainage. The pericardiocentesis removed 850 ml of a bluntly ematic effusion without clot. Two days later, 450 ml of blood more were drained. Cultures of the pericardial effusion for bacteria (aerobic and anaerobic), and fungi were performed and resulted to be negative. Moreover, Mantoux-Tine test for the research of Mycobacterium tuberculosis was negative too. To rule out viral etiology a complete virology screening (Parvovirus B19, adenovirus, echo-virus, Epstein-Barr virus, rubella virus, Citomegalovirus, and Coxakievirus) was performed, but it was negative as well as antibodies for autoimmune diseases. The cytological analysis did not find malignant cells, and a total body computed tomography scan ruled out the presence of cancer masses.
Serial TTEs were performed, and showed that pericardial effusion was stable after the drainage. The patient was discharged from the hospital in stable conditions without anticoagulation therapy. An ETT performed 1 month after discharge did not show pericardial effusion anymore.
dIScuSSIon
NOACs are as effective as VKAs in preventing stroke and systemic embolism and lowering the risk of major bleeding and rivaroxaban, an orally bioavailable FXa inhibitor, is one of the most used. [1] Although the use of rivaroxaban reduced the rate of bleedings, it has been found that more than 5% of bleedings reported in patients treated with NOACs occur in patients treated with rivaroxaban, with an incidence of fatal bleeds up to 0.4%. [2] Spontaneous hemopericardium in patients receiving NOACs is a rare condition, reported in patients treated with dabigatran [3, 4] apixaban [5] [6] [7] and rivaroxaban. [8] [9] [10] [11] [12] However, to the best of our knowledge, within reports of a spontaneous hemopericardium in patients treated with rivaroxaban, this is the first one in whom no other herbal products or drugs that may increase rivaroxaban blood levels by inhibiting P-glycoprotein and cytochrome P450 3A4 (CYP3A4) activity, or that increase the hemorrhagic risk, were taken. In detail, Shivamurthy et al. [8] reported that in their patient, the bleeding was probably caused by the contemporary intake of saw palmetto, an herbal product that could have to increase rivaroxaban activity. Similarly, Menendez and Michel, [9] Boone [10] and Oladiran et al. [11] reported that their patients took several other medications known to be metabolized through CYP3A4, underlining the risk that most physicians are familiar with recommendations to monitor renal function in patients prescribed rivaroxaban, but often fail to evaluate possible interactions with other agents having CYP3A4 inhibitory or inducer activity. Finally, Xu and MacIsaac [12] stated that their patient was treated with high doses of aspirin, ticagrelor, and ibuprofen.
The evidence that a potential life-threatening condition like a spontaneous hemopericardium could onset even when all the proper cautions in terms of renal function and drug interactions have been taken, raises some concerns about the lack of commercially available coagulation assays for the evaluation of anticoagulant levels in patients using NOACs and about the lack of antidotes. A new antidote for factor Xa inhibitors, Andexanet Alfa, has been recently tested in patients treated with Apixaban or rivaroxaban and it showed to markedly reduce anti-factor Xa activity and to have an excellent or good hemostatic efficacy at 12 h in 82% of patients. [13] However, this drug is not yet available in many countries.
concluSIon
In a scenario in which the number of patients receiving NOACs will increase in the next years, the evidence of uncommon, but dangerous complications are particularly important and reporting all possible adverse events associated with NOACs becomes essential. Clinicians should consider the possibility of hemopericardium in patients treated with NOACs who report dyspnea and have pericardial effusion on echocardiography, even when all the proper cautions in terms of renal function and drug interactions have been taken. 
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